Content Type: Article

  • European Health Data Space Regulation enters into force

    European Health Data Space Regulation enters into force

    ARTICLE

    European Health Data Space Regulation enters into force

    March 27, 2025

    Read time: 5 min

    Key takeaways
    Overview

    March 26, 2025, marked a pivotal moment in the EU with the European Health Data Space Regulation, (EU) 2025/327 (“EHDS Regulation”), coming into force. The EHDS represents a transformative initiative by the European Union aimed at amending the management and utilization of health data across its Member States. In an era when digitalization is reshaping healthcare, the EHDS seeks to establish a cohesive framework that enhances individuals’ access to and control over their personal electronic health data and fosters a robust environment for the secondary use of health data that benefits researchers and innovators.

    The most important changes the EHDS Regulation seeks to achieve include

    • Primary use: Improving access to and control of personal electronic health data across borders in the context of healthcare services
    • Secondary use: Enhancing the secure and trustworthy reuse of health data for research, innovation, policymaking, and regulatory activities
    • Electronic Health Records (“EHR”) : Laying down a uniform legal and technical framework, in particular for the development, marketing, and use of electronic health record systems, supporting both primary and secondary use

    The EHDS  will enable the EU to fully exploit the benefits of the secure and safe ex-change, use, and reuse of health data, serving the interests of patients, healthcare professionals, researchers, regulators, and innovators.

    Facilitating Healthcare Services with EU-wide Use of Health Data

    The EHDS Regulation creates a standardized digital framework for handling and sharing electronic health data to facilitate healthcare services that will significantly improve cross-border access to electronic health data, enabling healthcare professionals to effortlessly retrieve patient information from other EU countries. This will streamline administrative processes for international medical treatments and enhance the quality of healthcare.

    Rights and Responsibilities along the Healthcare System

    The EHDS regulation stipulates essential rights and responsibilities for various participants in the healthcare system, particularly for the following:

    • Data collection responsibilities:  Healthcare providers, including healthcare professionals, clinics and medical practices, within the EU are required to collect data for primary purposes.
    • Patients’ rights: Natural persons are granted specific rights to access, control, and share their personal electronic health data through an online service. However, these rights do not imply an obligation to digitize paper documents; they cover data that is already processed electronically.
    • Transmission responsibilities: Health data holders are required to extensively transmit data for secondary purposes.
    • Access rights: Healthcare professionals are provided access rights for primary purposes, while health data users (e.g., research institutions and life sciences companies) will have access and usage rights for secondary purposes.
    • Testing, standardization, and documentation responsibilities: Manufacturers, importers, and distributors of software and devices for electronic health records (EHR) must adhere to testing, standardization, and documentation requirements.

    Secondary Use of Health Data

    For many years, the secondary use of health data was fraught with legal uncertainties due to the absence of a clear legal basis, which impeded innovative research, especially in the field of artificial intelligence. The EHDS Regulation seeks to mitigate the previous uncertainties by providing a clear legal foundation for the secondary use of health data, in compliance with the General Data Protection Regulation (GDPR) and other data protection laws.

    Intellectual property rights and trade secrets are not considered to be an obstacle to the secondary use. Subject to the data holder flagging such rights or secrets to the health data access body, it will be the responsibility of the latter to determine whether protective measures should be put in place to protect the rights or secrets or if the permit application should be refused.

    The EHDS regulation explicitly defines permissible secondary purposes to include

    • Scientific research
    • Development and innovation of healthcare products or services
    • Training, testing, and evaluating algorithms in medical devices, AI systems, and digital health applications
    • Enhancing care, optimizing treatment, and healthcare delivery

    Health data cannot be used for prohibited purposes, such as advertising, marketing, or developing products or services that could harm individuals, public health, or society as a whole, as well as illegal drugs, alcoholic beverages, or tobacco and nicotine products.

    Provision of EHR Systems

    Besides the provisions on health data processing, the EHDS Regulation imposes product-specific responsibilities on manufacturers, importers, and distributors of so-called EHR systems (i.e., software and devices for electronic health records). These systems, comprising software or a combination of hardware and software, are designed to process health data in accordance with the EHDS Regulation. EHR systems are intended for use by healthcare providers in patient care or by patients enabling access to their health data.

    The EHDS Regulation imposes tiered responsibilities on economic operators based on their roles in the supply chain. While manufacturers must issue a declaration of conformity under the EHDS Regulation and affix the CE marking , importers can only market EHR systems that are in compliance with EHDS Regulation (i.e., they have the appropriate CE marking and are accompanied by sufficient instructions for use). Distributors, on the other hand, must verify that the manufacturer has issued a declaration of conformity. If the EHR systems include digital elements, then manufacturers, importers, and distributors must also adhere to the provisions of EU Regulation 2024/2847, the Cyber Resilience Act, which the EHDS Regulation complements regarding electronic health records.

    In depth
    Authors
    More insights

  • Antitrust Under Trump: March 2025 Updates

    Antitrust Under Trump: March 2025 Updates

    ARTICLE / CLIENT ALERT / US POLICY

    Antitrust Under Trump: March 2025 Updates

    March 26, 2025

    Read time: 4 min

    Key takeaways
    Overview

    As the Trump administration’s approach to antitrust takes shape through political appointments, policy statements, speeches, and enforcement actions, our team is tracking the latest developments and will provide important updates on issues pertinent to clients. This is not intended to be a comprehensive review of specific actions or cases, but rather an at-a-glance review of relevant policy as it is being created.

    View our initial client alert, “Antitrust Under Trump: Initial Policies and Actions.”

    In depth

    White House to Oversee Federal Trade Commission (FTC)

    • To ensure the FTC aligns with administration goals, President Donald Trump has given the White House oversight over the FTC’s actions, regulations, and policies, as well as those of other “independent” government agencies.
    • The FTC will now be required to establish a White House liaison and allow the White House to review proposed regulations and policies.

    Trump Fires Two Democratic FTC Commissioners

    • On March 18, 2025, President Trump fired the two Democratic commissioners, Rebecca Kelly Slaughter and Alvaro Bedoya, despite Supreme Court precedent that prevents the president from firing FTC commissioners over policy disagreements. Both commissioners plan to challenge the decision.
    • The FTC will continue to operate with Chairman Andrew Ferguson, Commissioner Melissa Holyoak, and Mark Meador (assuming he is confirmed).

    Gail Slater Confirmed to Lead US Department of Justice (DOJ) Antitrust Division

    • The US Senate overwhelmingly approved the nomination of Gail Slater to be the Assistant Attorney General (AAG) of the DOJ on March 11, with a vote of 78 to 19.

    Senate Commerce Committee Approves Mark Meador as FTC Commissioner

    • On March 12, the US Senate Committee on Commerce, Science, and Transportation approved Mark Meador’s nomination to become an FTC commissioner with a vote of 20-8, sending the vote to the Senate floor.
    • The president’s subsequent firing of Commissioners Slaughter and Bedoya may complicate the final Senate vote, but the FTC currently has a quorum of two Republicans, allowing it to act without additional commissioners in place.

    Antitrust Division to Watch Costs, Leverage In-House Economists

    • In a memo to staff on March 13, AAG Slater indicated that the Division will seek to cut costs by focusing its resources on markets that significantly impact consumers or are crucial to national security. The Division will review its use of expensive third-party economic consultants, often relied upon for trial testimony, and instead “utilize and maximize” the talents of its in-house economists.

    Ferguson Pursues Litigation Against Big Tech While Streamlining Transactions

    • During an interview, Chairman Ferguson explained that the FTC will continue to devote resources toward pending cases against Big Tech companies. Other priorities include healthcare and protecting labor markets.
    • Ferguson also stated that while the American free market system depends on antitrust enforcement, if a transaction has no antitrust issue, the FTC will not try kill it. Instead, it will “get out of the way” and focus on deals that pose real antitrust threats to American consumers.

    Holyoak Wants the FTC to Focus on Economics

    • In a speech, Commissioner Holyoak criticized the Biden administration for forcing settlements, bringing cases built on “flimsy legal bases,” and downplaying economic factors in antitrust enforcement actions.
    • Holyoak said that economics is critical to the FTC’s work and expects an increased emphasis on economics under Chairman Ferguson.
    Authors

    Jon B. Dubrow

    Partner

    Washington, DC

    Michelle Lowery

    Partner

    Los Angeles, Chicago

    Megan C. Ingram

    Associate

    Washington, DC

    More insights

  • Corporate Transparency Act: Insights and Resources

    Corporate Transparency Act: Insights and Resources

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act: Insights and Resources

    October 2023

    Read time: 9 min

    Key takeaways
    Overview

    The US Corporate Transparency Act (CTA) has undergone significant changes since it was first implemented. Enacted to enhance financial transparency and strengthen anti-money laundering efforts, the CTA established a framework requiring corporations, limited liability companies, limited partnerships, and other similar entities to disclose beneficial ownership information to the Financial Crimes Enforcement Network (FinCEN), a bureau within the US Department of the Treasury.

    On March 26, 2025, FinCEN issued an interim final rule that eliminates the beneficial ownership information (BOI) reporting requirement for US companies and US persons under the CTA. Foreign entities that meet the new definition of a “reporting company” and do not qualify for an exemption from the reporting requirements must report their BOI to FinCEN under the applicable deadlines; however, these foreign entities will not be required to report any US persons as beneficial owners, and US persons will not be required to report BOI with respect to any such entity for which they are a beneficial owner. More details can be found at FinCEN’s Beneficial Ownership Information Reporting page.

    While the CTA continues to represent a major shift in beneficial ownership reporting, its scope has been substantially narrowed, reshaping the compliance landscape for both US and international stakeholders.

    Explore our collection of insights and resources to stay up to date on the CTA. McDermott can help you navigate these complex rules and determine how they may apply to you and the entities you own or control.

    Insights

    Corporate Transparency Act Update: Penalties Paused & Significant Reduction in Scope Expected in Forthcoming Rulemaking (3/10/25): On March 2, 2025, the US Department of the Treasury (“Treasury”) issued a press release clarifying that Treasury will not enforce any penalties or fines associated with the Corporate Transparency Act’s (“CTA”) implementing regulation (“Reporting Rule”) under the existing deadlines and will “not enforce any penalties or fines against U.S. citizens or domestic reporting companies or their beneficial owners after the forthcoming rule changes take effect.” In the press release, Treasury also stated that it will be “issuing a proposed rulemaking that will narrow the scope of the [Reporting Rule] to foreign reporting companies only.”

    CTA Penalties Suspended; New Rulemaking Proposed (3/4/25): The Financial Crimes Enforcement Network (FinCEN) and the US Department of the Treasury have announced that no penalties or fines will be imposed for failing to submit a beneficial ownership information (BOI) report by the recently announced March 21, 2025, deadline. Additionally, no penalties or fines will be imposed on US citizens or “domestic reporting companies” (or their “beneficial owners”) in connection with BOI reporting. FinCEN also intends to issue a new reporting rule later this year – including an interim rule in the coming weeks to extend reporting deadlines – that may significantly change current reporting obligations. These latest announcements provide some certainty regarding FinCEN’s approach to penalties and fines for failing to file BOI reports and its intent to change the current reporting rules.

    Corporate Transparency Act Update: Reporting Obligations Reinstated (2/19/25): On February 18, 2025, the US District Court for the Eastern District of Texas in Smith v. US Department of the Treasury, No. 6:24-cv-336-JDK, entered an order staying (pausing) the nationwide preliminary injunction against enforcement of the Beneficial Ownership Information Reporting Requirements final rule (31 C.F.R. 1010.380) (Reporting Rule) promulgated under the Corporate Transparency Act (CTA) (31 U.S.C. § 5336). Prior to this order, enforcement of the CTA and the Reporting Rule was on hold. On February 18, 2025, in light of this order, the Financial Crimes Enforcement Network (FinCEN) issued a notice that beneficial ownership information (BOI) reporting requirements under the CTA are once again back in effect.

    Corporate Transparency Act: Nationwide Injunction Continues (1/24/25): On January 24, 2025, a day after the US Supreme Court stayed a nationwide injunction against enforcing the Corporate Transparency Act (CTA), the Financial Crimes Enforcement Network (FinCEN) issued an alert that, in light of a separate court order issued on January 7, 2025, reporting companies are still not required to file beneficial ownership information reports (BOIRs) with FinCEN. While the January 7 order in the case of Smith v. US Department of Treasury remains in effect, reporting companies are not required to file BOIRs with FinCEN and are not subject to liability if they fail to do so while the order remains in force.

    Fifth Circuit Reinstates Nationwide Injunction Against Enforcement of the CTA (12/27/24): On December 26, 2024, in response to an emergency motion for rehearing filed by plaintiffs, the US Court of Appeals for the Fifth Circuit reinstated the nationwide preliminary injunction against enforcement of the Corporate Transparency Act (CTA) (31 U.S.C. § 5336) and the Beneficial Ownership Information Reporting Requirements final rule (Final Rule) promulgated thereunder (31 C.F.R. 1010.380).

    Corporate Transparency Act Update: Nationwide Injunction Stayed; Deadlines Extended (12/26/24): On December 23, 2024, in response to an emergency motion by the US Department of Justice, the US Court of Appeals for the Fifth Circuit stayed the nationwide preliminary injunction against enforcement of the Corporate Transparency Act (CTA) (31 U.S.C. § 5336) and the Beneficial Ownership Information Reporting Requirements final rule (Final Rule) promulgated thereunder (31 C.F.R. 1010.380), which was entered by the US District Court for the Eastern District of Texas on December 3, 2024, in Texas Top Cop Shop, Inc., et al. v. Garland, No. 4:24-cv-00478 (E.D. Tex).

    Corporate Transparency Act: What to Know (12/18/23): The CTA introduces beneficial ownership reporting requirements effective January 1, 2024, for new and existing companies. This article outlines the new reporting obligations imposed by the CTA.

    Understanding the Corporate Transparency Act’s Company Reporting Obligations (10/16/23): Starting January 1, 2024, the CTA will mandate all new companies formed or qualified to do business in the United States (and by January 1, 2025, all companies formed or qualified to do business in the US prior to January 1, 2024) to report beneficial ownership information (BOI) to FinCEN. The CTA will require companies to report BOI unless they fit within defined exemptions. This article outlines which companies are impacted, what information they must report, the penalties for failing to report and other guidance related to the CTA.

    Unpacking CTA Disclosure Complexity with Private Trust Companies (9/8/23): Most family-owned entities will need to comply with beneficial ownership information reporting requirements under the CTA. In this Bloomberg Tax article, McDermott lawyers Harry Dao and Elise McGee examine whether a private trust company (PTC) can help lessen the disclosure burden under the CTA, analyzing whether a PTC can qualify for a CTA exemption and whether an entity owned by one or more trusts of which the PTC serves as a fiduciary can qualify for a CTA exemption.

    FinCEN Seeks Guidance on Applying CTA Reporting Obligations to Trusts and Estates (1/10/22): The CTA is expected to impose reporting obligations on certain types of trusts and various individuals related to trusts; however, it does not explicitly address many types of trusts commonly used in US estate planning. In response, FinCEN released proposed regulations governing the CTA and has requested comment on how to apply the proposed regulations to certain kinds of trusts. This article provides a glimpse into how the CTA may apply to trusts and details timing and penalties for reporting to FinCEN.

    FinCEN Announces Anti-Money Laundering Priorities (7/16/21): FinCEN issued its government-wide anti-money laundering (AML) and countering the financing of terrorism (CFT) priorities in June 2021. The AML/CFT priorities demonstrate that the Biden administration considers enhanced AML requirements, regulations and enforcement to be key components of its criminal and civil enforcement efforts, and important tools to address many of the broader issues confronting the US and the international community. This article explores how these priorities may impact companies and details the steps companies should take now to prepare for enhanced AML regulations and enforcement activity.

    President Biden Elevates Anticorruption Enforcement (6/7/21): President Biden’s memorandum on Establishing the Fight Against Corruption as a Core United States National Security Interest ushers in a new era of collaboration between federal agencies and establishes a whole-of-government approach to fighting global corruption in furtherance of the national security interests of the US. This article outlines the steps companies should take to position themselves in this new era of compliance.

    The Corporate Transparency Act: New Beneficial Ownership Reporting Requirements (2/12/21): On January 1, 2021, the US Congress passed the National Defense Authorization Act (NDAA). Found within the NDAA is the CTA, which will require corporations, limited liability companies and other similar entities to disclose BOI to FinCEN. Companies should carefully review the CTA to determine whether they are “reporting companies” and evaluate their potential obligations under the forthcoming regulations.

    Congress Passes the Corporate Transparency Act—Overriding Presidential Veto (12/15/20): On December 11, 2020, and by a veto-proof majority, the US Senate joined the US House of Representative in passing the NDAA for Fiscal Year 2021, which includes the CTA. The CTA requires a report to be filed with FinCEN that identifies each beneficial owner of an applicant forming a reporting company. While questions remain as to the full implications of the Act, it represents an important step in the right direction for the United States in the battle against money laundering and terrorist financing.

    Webinars

    Reporting for Duty: Preparing for the Corporate Transparency Act (7/25/23): This webinar explores the changes introduced under the CTA and their impact on family offices, including new reporting and disclosure requirements. Click the link above to read the key takeaways, watch the webinar replay and download the slides.

    Resources

    In depth
    Authors
    More insights

  • SEC Backs Down on Ripple Appeal as Crypto Stance Shifts

    SEC Backs Down on Ripple Appeal as Crypto Stance Shifts

    ARTICLE / CLIENT ALERT

    SEC Backs Down on Ripple Appeal as Crypto Stance Shifts

    March 26, 2025

    Read time: 7 min

    Key takeaways
    Overview

    It is official — the SEC has reversed course on its approach to crypto enforcement. After five years of litigation against Ripple Labs for allegedly selling an unregistered security, the XRP token, the SEC, on March 19, 2025, announced that it intends to drop its appeal. This decision is the latest in a series of actions taken by the SEC marking a radical shift in regulating digital assets.

    The SEC’s decision to drop its appeal comes amid sweeping changes in the SEC’s approach to crypto. This includes the launch of a Crypto Task Force, led by Commissioner Hester M. Peirce, aimed at establishing clear regulatory boundaries. Commissioner Peirce has also signaled a new direction for crypto oversight, emphasizing a more structured, transparent and navigable framework. Additionally, the SEC has issued fresh guidance that “meme coins” are not securities, further reflecting its evolving stance on digital assets.[1]

    Prior SEC Litigation

    The SEC sued Ripple in December 2020, alleging that its XRP token was sold as an unregistered security. In July 2023, Judge Analisa Torres ruled that XRP was a security when sold to institutional investors but not when sold on public exchanges. In August 2024, Ripple was ordered to pay $125 million in penalties, with the court reaffirming that secondary sales were not securities transactions. Both Ripple and the SEC appealed different parts of the ruling, but before briefing began, Ripple announced the SEC’s intent to drop its appeal. Now “in the driver’s seat,”[2] Ripple is weighing how best to pursue its cross appeal, which could further clarify legal boundaries for crypto asset sales.

    Notably, the SEC’s decision to drop the Ripple appeal follows its recent win in the Terraform Labs case, heard in the same district as Ripple. Unlike in Ripple, Judge Jed Rakoff ruled that secondary-market buyers had a reasonable expectation that Terraform would use their investments to generate profits — aligning with the Howey test and supporting the SEC’s argument that the tokens should be considered securities. This ruling was seen as a major victory for the SEC’s position at that time and a direct rebuttal of the approach taken in Ripple. The SEC’s move marks a significant moment in its evolving approach to crypto regulation — one that appears to prioritize strategic withdrawals over sweeping enforcement battles.

    Takeaway

    It is clear the SEC has recalibrated its approach on crypto. Other regulators, both in the US and globally, may follow suit — some adopting a similarly lighter touch, while others move to tighten oversight to address gaps and exert greater control. Meanwhile, Congress’ role in shaping new crypto regulations remains uncertain, with legislative efforts still in flux. Given this evolving landscape, firms must stay vigilant and continue to closely monitor new developments.

    Authored by Stephanie Breslow, Craig Warkol and Kolby Loft.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See SEC Division of Corporation Finance, “Staff Statement on Meme Coins” (Feb. 27, 2025). For more guidance on the SEC’s meme coin guidance see Schulte Roth & Zabel, “SEC’s Division of Corporation Finance Says Meme Coins Are Not Securities”, (March 3, 2025), available at /insights/secs-division-of-corporation-finance-says-meme-coins-are-not-securities/. 

    [2] @s_alderoty, X, (March 19, 2025, 9:16 AM)


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Stephanie R. Breslow

    Partner

    New York – 919 Third Avenue

    More insights

  • SEC Eases Marketing Rule Net Performance Requirement

    SEC Eases Marketing Rule Net Performance Requirement

    ARTICLE / CLIENT ALERT

    SEC Eases Marketing Rule Net Performance Requirement

    March 24, 2025

    Read time: 5 min

    Key takeaways
    Overview

    What You Need to Know

    On March 19, 2025, the US Securities and Exchange Commission’s (SEC) Division of Investment Management updated its frequently asked questions (FAQs) related to Rule 206(4)-1 (the Marketing Rule) under the Investment Advisers Act of 1940, as amended. The two additional FAQs permit registered investment advisers to present – subject to the satisfaction of certain conditions – the following performance and performance-like metrics in marketing materials on a gross-only basis:

    • The performance of a single investment or group of investments (e.g., case studies) in a private fund or other portfolio (Extracted Performance).
    • Certain portfolio or investment characteristics (e.g., yield, coupon rate, contribution to return, volatility, sector or geographic returns, attribution analyses, the Sharpe ratio, and other similar metrics) (Portfolio Characteristics).

    This guidance is a welcome relief for private fund advisers who not only have struggled with how to present Extracted Performance and Portfolio Characteristics on a net basis since the Marketing Rule’s November 2022 compliance date but also had concerns that presenting these metrics on a net basis has led to confusing and potentially misleading performance results.

    Advisers who include Extracted Performance and Portfolio Characteristics in their marketing materials should consider whether that information would be more meaningfully presented in a manner that aligns with the FAQs. To the extent that advisers revise their marketing materials, they should ensure compliance with the conditions outlined in the FAQs and the Marketing Rule’s other requirements. Advisers may also need to update their Marketing Rule compliance policies to align with any changes to their marketing materials.

    In depth

    Background

    Among other things, the Marketing Rule requires that any presentation of gross performance be accompanied by net performance presented with at least equal prominence to (and in a format designed to facilitate comparison with) gross performance calculated using the same methodology and over the same time period.

    Compliance with this requirement brought challenges for private fund advisers presenting Extracted Performance since a fund’s fees and expenses are applied at the fund level. While the industry adopted various methodologies to satisfy this requirement, there was concern across the industry that the results were confusing to investors and potentially more misleading than presenting Extracted Performance on a gross-only basis with adequate disclosures. Prior SEC guidance failed to alleviate these challenges.

    It also remained unclear under the Marketing Rule and prior guidance whether Portfolio Characteristics were considered “performance” for purposes of the Marketing Rule’s net requirement. Without articulating a position as to whether any particular Portfolio Characteristic would be considered “performance”[1], the SEC noted that even if Portfolio Characteristics are considered performance for purposes of the Marketing Rule, calculating these characteristics net of fees and expenses is challenging and may lead to misleading or confusing results. Therefore, the SEC articulated its view that (1) so long as an adviser prominently displays the gross and net performance of the total portfolio calculated pursuant to the requirements of the Marketing Rule and (2) in a manner that is not otherwise materially misleading and provides appropriate accompanying information about the Portfolio Characteristic and how it is calculated, there is little risk that prospective investors will be misled about the impact of fees and expenses on their returns when viewing such a characteristic.

    Gross-Only Performance Conditions

    As set out in the FAQs, investment advisers may present Extracted Performance and Portfolio Characteristics on a gross-only basis, provided the following conditions are satisfied:

    • The Extracted Performance and Portfolio Characteristics are clearly identified as being calculated on a gross-only basis and do not reflect the deduction of fees and expenses.
    • The Extracted Performance and Portfolio Characteristics are accompanied by a presentation of the total portfolio’s gross and net performance consistent with the requirements of the Marketing Rule.
    • The gross and net performance of the total portfolio is presented with at least equal prominence to, and in a manner designed to facilitate comparison with, the gross-only Extracted Performance or Portfolio Characteristics.
    • The gross and net performance of the total portfolio is calculated over a period that includes the entire period over which the Extracted Performance and Portfolio Characteristics are calculated.

    The SEC noted that any advertisement that presents gross-only Extracted Performance or Portfolio Characteristics in accordance with the FAQs remains subject to the general prohibitions of the Marketing Rule.

    Authors

    Allison Scher Bernbach

    Partner

    New York – One Vanderbilt Avenue

    Ian M. Schwartz

    Partner

    New York – One Vanderbilt Avenue

    Prem Amarnani

    Partner

    New York – One Vanderbilt Avenue

    Alissa Cardillo

    Partner

    New York – One Vanderbilt Avenue

    Luc Jansen

    Partner

    New York – One Vanderbilt Avenue

    Erica Moscarello

    Partner

    New York – One Vanderbilt Avenue

    David Nestler

    Partner

    New York – One Vanderbilt Avenue

    Lauren Nevidomsky

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • California AB 2319 Expands Implicit Bias Training for Perinatal Care Providers

    California AB 2319 Expands Implicit Bias Training for Perinatal Care Providers

    ARTICLE / CLIENT ALERT

    California AB 2319 Expands Implicit Bias Training for Perinatal Care Providers

    March 24, 2025

    Read time: 4 min

    Key takeaways
    Overview

    California legislators enacted Assembly Bill (AB) 2319 last fall in a landmark attempt to reduce racial and ethnic disparities in maternal and infant healthcare by addressing implicit bias in pregnancy, childbirth, and postnatal care to create a more equitable healthcare system. The bill expands and strengthens implicit bias training for healthcare providers and explicitly recognizes birthing people to include nonbinary persons and persons of transgender experience. AB 2319 builds upon the California Dignity in Pregnancy and Childbirth Act (Senate Bill (SB) 464), which aimed to reduce maternal mortality rate among persons of color.

    Together, AB 2319 and SB 464 represent steps by California legislators toward achieving health equity at a time when healthcare providers that receive federal funds must ensure their actions comply with US President Donald Trump’s executive orders on diversity, equity, and inclusion (DEI) and gender ideology. Providers subject to the executive orders will need to review their implicit bias training to ensure it satisfies the requirements of AB 2319 in a facially race-neutral manner.

    In depth

    AB 2319 mandates that all healthcare providers involved in perinatal care, as well as those regularly interacting with perinatal patients, complete the revised implicit bias training by June 1, 2025, for current providers and within six months for new hires. This training must now cover the recognition of intersecting identities and the multiple layers of potential biases that could harm patients and their infants.

    The bill explicitly requires all physician assistants, medical assistants, licensed vocational nurses, and doctors and individuals licensed under Division 2 of the California Business and Professions Code who provide perinatal care to complete the implicit bias training.

    Additionally, starting February 1, 2026 (and each year thereafter), all hospitals, alternative birth centers, and primary care clinics providing perinatal care must provide proof of compliance with the implicit bias training requirements to the state attorney general, including the names of the providers and the date they completed the training. The bill authorizes the attorney general to pursue civil penalties of $5,000 for the first violation and $15,000 for each subsequent violation, plus attorneys’ fees and costs. The attorney general may also post on its website the names of the facilities that failed to submit proof of compliance.

    Hospitals, alternative birth centers, and primary care clinics receiving federal funding must also ensure that the implicit bias training complies with the executive orders. On March 14, 2025, the US Court of Appeals for the Fourth Circuit halted the previously issued preliminary injunction against the executive orders, allowing the government to resume targeting DEI programs pending appeal. As a result, providers subject to the executive orders will need to review their implicit bias training programs to ensure they satisfy the requirements of AB 2319 in a facially race-neutral manner, such as by utilizing statistics across all racial demographics in training sessions.

    Takeaways


    Facilities subject to AB 2319 should review and update their implicit bias training programs to reflect the changes implemented by the bill. They should also establish systems to track the completion of the training programs in preparation of the yearly reporting requirements imposed by AB 2319. Further, facilities must carefully navigate the complex intersection between complying with federal and state laws.

    Please contact one of the authors of this article or your regular McDermott lawyer(s) to discuss the potential legal implications of AB 2319 and President Trump’s executive orders on your business.

    Authors

    Pankit J. Doshi

    Partner

    San Francisco, Silicon Valley

    Travis Jackson

    Partner

    Los Angeles

    Alejandra Chumbes

    Associate

    San Francisco

    More insights

  • New Trump Administration Tariff Developments

    New Trump Administration Tariff Developments

    CLIENT ALERT / US POLICY

    New Trump Administration Tariff Developments

    March 21, 2025

    Read time: 8 min

    Key takeaways
    Overview

    On February 1, 2025, using authority under the International Emergency Economic Powers Act (IEEPA) and other legal provisions, President Donald Trump signed three executive orders (EOs) imposing new tariffs on all goods from Canada, Mexico, and China effective February 4.

    On February 3, the administration paused the planned tariffs on goods from Canada and Mexico until March 4, pending negotiations. In response, Canada also paused its planned retaliatory tariffs. After the new US tariffs took effect on March 4, the White House on March 5 announced that autos and auto parts from Canada and Mexico that meet the terms of the United States’ free trade agreement with those countries (USMCA) will be exempted from the new tariffs authorized by the February 1 EOs. The White House announced on March 6 that effective March 7, all goods from Mexico and Canada that qualify for USMCA preference will also be exempted from the 25% tariff under these EOs. On March 4, in response to the new US tariffs imposed on March 4, Canada implemented a first round of retaliatory tariffs on US goods shipped to Canada and threatened a larger round of retaliation after a public comment period ends. Canada has since stated that despite the March 5 and 6 amendments made by President Trump to the February 1 EOs, Canada will continue to impose its March 4 retaliatory measures but will pause its second round of retaliation.

    The February 1 EO imposing 10% tariffs on all goods from China took effect on February 4, and China announced countermeasures effective February 10. On March 3, President Trump amended the February 1 EO to increase the tariff on all products from China from 10% to 20%, effective March 4. In response, China on March 4 announced additional retaliatory tariffs on US goods to take effect on March 10.

    On February 10, President Trump signed two proclamations reinstating 25% tariffs on imports of steel and steel derivatives and increasing from 10% to 25% the tariff on imports of aluminum and aluminum derivatives. These 25% tariffs took effect on March 12. In response, Canada imposed further retaliatory tariffs on US goods. The European Union (EU) also announced retaliatory measures in response to the steel and aluminum tariffs but has delayed their implementation until mid-April.

    On February 13, President Trump instructed the US government agencies responsible for trade to conduct a review and investigation to determine the appropriate “reciprocal” tariffs to apply to each trading partner that discriminates against US trading interests. He has said these new reciprocal tariff rates will be announced on April 2.

    In depth

    US Tariffs on China

    Details

    Under the February 1 EO, as amended by the March 3 EO, all US imports from China are currently subject to an additional 20% tariff. That 20% rate is on top of each entering good’s normal US tariff rate and all other applicable tariffs.

    The 20% tariff is being applied over concerns about the adequacy of the measures being taken by China to control fentanyl exports and money laundering by transnational criminal gangs.

    Retaliatory Measures by China

    To date, China has issued two rounds of retaliatory tariffs. The first list of tariffs took effect on February 10, the second on March 10. China’s new retaliatory rates cover a wide array of US goods.

    China has also responded by taking non-tariff punitive measures that impact US entities and US trade interests.

    US Tariffs on Canada and Mexico

    Details

    The February 1 EOs imposing 25% tariffs on goods from Mexico and all goods from Canada except for energy resources, which are subject to a 10% tariff, took effect on March 4. The White House announced on March 5 that no duties will be applied under these EOs on autos and auto parts from Mexico and Canada that qualify for USMCA preference. It announced on March 6 that effective March 7, no duties will be applied under these EOs on all goods from Mexico and Canada that qualify for USMCA preference. Its March 6 EO amendment provides, however, that goods that do not qualify for USMCA preference will continue to be subject to the 25% tariff under the EOs, except in the case of non-qualifying potash from both countries, which will be subject to a 10% rate, and non-qualifying energy resources from Canada, which will also be subject to a 10% rate.

    The February 1 EO states that the new tariffs are being applied due to concerns that Mexico and Canada have failed to take sufficient action to stem cross-border migration and drug trade. President Trump has reiterated that justification following implementation of these new rates and encouraged companies producing in both countries to move their production to the United States to avoid the new tariffs.

    Retaliatory Measures by Canada and Mexico

    On March 4, following implementation of the February 1 EO, Canada imposed its first round of retaliatory tariffs on $21 billion of US goods and opened a comment period on a list of additional US targeted goods totaling $83 billion. After President Trump greatly scaled back the February 1 EO on March 5 and 6, Canada announced that it was retaining its March 4 retaliatory tariffs but pausing further action on its second round of retaliatory measures.

    Mexico has said that for now it will not proceed with retaliation against US goods.

    Steel and Aluminum Tariffs

    Details

    On February 10, President Trump signed two proclamations closing existing loopholes and exemptions to the Section 232 tariffs on imports of steel and aluminum and derivatives. The proclamations terminated on March 12 the existing steel and aluminum “alternative arrangements” with Argentina, Australia, Brazil, Canada, the EU, Japan, Mexico, South Korea, Ukraine, and the United Kingdom. Effective March 12, all imports of steel products and covered derivatives once again became subject to the 25% Section 232 steel tariff originally authorized in 2018. Similarly, as of March 12, all imports of aluminum products and covered derivatives, regardless of whether they were covered by these alternative arrangements, became subject to a 25% rate. The 25% rate on aluminum imports materially increased the original 10% Section 232 aluminum tariff authorized in 2018.

    Additionally, the proclamations terminated on March 12 the current steel and aluminum exclusions that had previously been granted under the Commerce Department’s exclusion procedures. The proclamations also terminated the steel and aluminum exclusion procedures previously administered by Commerce.

    Responses from Impacted Trading Partners

    After the new steel and aluminum tariffs took effect on March 12, Canada imposed a further round of retaliatory tariffs on an additional $21 billion worth of US goods. The EU also announced retaliatory tariffs on $28 billion worth of US goods but said on March 20 it would delay the implementation of those new rates until mid-April.

    Mexico, the UK and other impacted trading partners have said they will await President Trump’s announcement of “reciprocal” tariffs before determining how to respond to the increased steel and aluminum tariffs.

    “Reciprocal” Tariffs

    Details

    President Trump’s new “reciprocal” tariff rates for each trading partner will be calculated based on each trading partner’s tariff and non-tariff measures, unfair subsidies, intellectual property violations, investment restrictions, regulatory restrictions, services restrictions, technical barriers to trade, and other structural and/or sector-specific barriers used by that trading partner that burden or restrict US trade interests.

    President Trump has stated that the new reciprocal rates will be announced on April 2.

    Responses from Potentially Impacted Trading Partners

    No trading partner has yet formally announced countermeasures, but the EU and Canada have informally stated their intention to retaliate if reciprocal tariffs are imposed on their goods.

    “Industry” Tariffs

    Details

    In addition to the February 10 EO announcing new steel and aluminum tariffs, President Trump issued an EO on February 25 announcing a new Section 232 national security investigation on copper and derivative products. Public comments are due by April 1. This investigation is expected to lead to further US tariffs on copper and derivative products.

    President Trump issued another EO on March 1 announcing a new Section 232 national security investigation on timber, lumber, and derivative products. Public comments are due by April 1. This investigation may lead to further tariffs on timber, lumber, and derivative products.

    President Trump has also informally stated his intention to impose new tariffs on imports of autos, semiconductors, and pharmaceuticals but has not yet clarified how or when these new rates will be implemented.

    Responses from Impacted Trading Partners

    No trading partner has yet formally responded to these industry investigations and tariff threats.

    Commercial Implications

    Many clients engaged in global trade are incurring significantly increased costs, supply chain disruptions, and trade uncertainty.

    Tariff Mitigation Steps

    McDermott lawyers are advising clients on the evolving tariff outlook and counseling on commercial strategies to mitigate the new tariff impacts. Reach out to the authors or your regular McDermott lawyer to stay informed and seek legal counsel on how best to navigate these wide-reaching tariff challenges.

    Authors

    Carolyn B. Gleason

    Partner

    Washington, DC

    Debra A. Harrison

    Partner

    Washington, DC

    David J. Levine

    Senior Counsel

    Washington, DC

    Raymond Paretzky

    Counsel

    Washington, DC

    More insights

  • EDGAR Next: Preparing for the SEC’s Filing System Transition

    EDGAR Next: Preparing for the SEC’s Filing System Transition

    ARTICLE / CLIENT ALERT

    EDGAR Next: Preparing for the SEC’s Filing System Transition

    March 21, 2025

    Read time: 17 min

    Key takeaways
    Overview

    In 2024, the SEC adopted amendments to the rules and forms related to its EDGAR filing system that will impact the way all filers access and manage their EDGAR accounts and make electronic filings with the SEC.[1] These changes—referred to as “EDGAR Next”—are intended to improve the security of and modernize EDGAR and will affect all filers who submit filings electronically on EDGAR. As part of the transition to EDGAR Next, filers will have to enroll and designate individuals who will be responsible for managing their EDGAR accounts, and the SEC will phase out filers’ ability to use shared EDGAR access codes to make filings.

    Starting on March 24, 2025, existing filers will be able to begin enrolling in EDGAR Next through the new EDGAR Filer Management dashboard, and prospective new filers will be required to electronically submit an amended Form ID on the dashboard to apply for EDGAR access. In order to avoid interruption in the ability to file, existing filers will need to enroll in EDGAR Next no later than Sept. 12, 2025.

    There is no downside to enrolling early in EDGAR Next, and we encourage you to take advantage of the enrollment period (March 24, 2025 to Sept. 12, 2025) to enroll each of your entities/individuals who may make EDGAR filings. During the enrollment period, filers will continue to be able to submit filings using the current password-based access system and the same processes used prior to EDGAR Next.

    What to Expect with EDGAR Next:

    • New Filer Management Dashboard
      • The SEC is launching a new dashboard on the EDGAR Filer Management website to allow filers to manage their accounts and to make filings on March 24, 2025
      • The dashboard will be used to enroll current filers, apply for EDGAR access, authorize individuals to manage a filer’s account or submit filings on behalf of a filer, view EDGAR codes, connect EDGAR application programming interfaces (“APIs”), and to submit required annual confirmations for an EDGAR filer
    • Requirement for Individual Account Credentials
      • Historically, filers accessed EDGAR using a CIK and a single set of shared access credentials (such as a password, CCC, PMAC, and passphrase), and anyone with access to these credentials was able to make filings and manage the filer’s EDGAR account
      • Under EDGAR Next, persons accessing EDGAR to make filings, manage EDGAR accounts or view the new dashboard will be required to use their own individual Login.gov account credentials[2] (and complete a multifactor authentication) and must first be authorized/designated to act on behalf of each filer
      • The public EDGAR site to view filings will still be accessible without credentials
    • Designation of Account Administrators and Other Roles
      • Each filer will generally be required to designate at least two individuals as “account administrators” to manage its EDGAR account using the dashboard[3]
      • Account administrators can add individuals to specific roles (i.e. additional account administrators, “users” that can make filings and “technical administrators” to connect to EDGAR APIs) for each filer
      • Account administrators can delegate the authority to make filings on the filer’s behalf to third parties, such as law firms, broker-dealers, printers or other filing agents
      • Each administrator or other user will need individual Login.gov account credentials
    • Delegation of Filing Authority
      • In order for third parties, including law firms, broker-dealers, printers and other filing agents, to make filings on behalf of a filer, an account administrator must first delegate filing authority to such third party’s EDGAR account by using the dashboard
        • Delegated entities will be able to make EDGAR submissions on the filer’s behalf but will not otherwise have access to the filer’s dashboard
      • Filers should contact each of their filing agents to obtain delegation instructions; it’s possible that multiple delegations may be necessary (for example, if your law firm sometimes uses an outside printer, you may need to authorize both the law firm and the printer)
      • Compliance by September 15 is Mandatory
        • Starting Sept. 15, 2025, filers will no longer be able to submit filings using the legacy password-based access system, and enrollment on EDGAR Next will be mandatory for filers to manage their accounts or submit filings
        • Filers will continue to be able to submit filings using the current password-based access system and the same processes used prior to EDGAR Next through September 12
      • New Annual Confirmation Requirement
        • An account administrator for each filer will have to confirm annually that all of the individuals and entities on the filer’s dashboard are authorized by the filer to act on its behalf and that all information related to the filer on the dashboard is accurate
        • Account administrators will be able to select which quarter-end date will be the filer’s ongoing confirmation deadline (March 31, June 30, September 30 or December 31)
        • If the annual confirmation is not made within three months after the deadline, the filer’s EDGAR account will be deactivated and it will not be able to make filings until it re-enrolls in EDGAR Next by submitting the new Form ID

    Existing Filers: Enrolling in EDGAR Next

    Filers who have current EDGAR codes can enroll during the enrollment period without having to submit the new Form ID, obtain a power of attorney or notarize any documents. In order to avoid interruption in the ability to file, existing filers will need to enroll in EDGAR Next no later than Sept. 12, 2025.[4] Filers will continue to be able to submit filings using the current password-based access system and the same processes used prior to EDGAR Next through September 12.

    How to Enroll in EDGAR Next:

    • Obtain individual Login.gov account credentials
      • The person who enrolls the filer and each account administrator will need individual Login.gov account credentials to access the EDGAR dashboard
      • View instructions on how to create a Login.gov account
        • It is recommended to use your business email address to sign up for EDGAR purposes, even if you already have a Login.gov account using your personal email
      • Collect current EDGAR access codes (CIK, CCC and passphrase)
        • You will need the CIK, CCC and passphrase for each filer in order to enroll into EDGAR Next during the enrollment period
          • If your CCC and/or passphrase has not been reset since September 2019 or you don’t have access to such codes, then you may need to reset these codes by following these instructions
        • Identify account administrators for each filer
          • Filers will need to designate at least two account administrators (except for individuals and single member company filers, who need to designate at least one account administrator)
          • You will need the name, email address (which must match such person’s Login.gov credentials), business address and business telephone number for each account administrator
        • Enroll in EDGAR Next using the dashboard between March 24 and September 12
          • Login to the dashboard using your Login.gov account credentials and click “Enroll in EDGAR Next”
          • You can manually enroll individual EDGAR accounts, or bulk enroll multiple EDGAR accounts simultaneously using the CSV template available on the dashboard
          • During enrollment, you must choose an annual confirmation date for each filer (March 31, June 30, September 30 or December 31)
          • Note that enrollment will automatically reset the filer’s CCC, which EDGAR will continue to require in order to make filings; the new CCC will be visible on the dashboard to any account administrator, user, or delegated entity
        • Delegate authority to file to necessary third parties
          • If a filer uses a third party such as a law firm, broker-dealer, printer or other filing agent to make filings, an account administrator must first delegate authority to file to such third party’s EDGAR account using the dashboard; filers should coordinate with each of its filing agents for necessary instructions
            • If a public company submits Section 16 filings on behalf of any of your filers that serve as directors, you should coordinate with the company with respect to the delegation of authority to file on their behalf

    New Filers: Applying for EDGAR Access on Form ID

    Beginning March 24, 2025, any prospective new filer that will need EDGAR codes will need to apply using the amended Form ID using the EDGAR dashboard with Login.gov credentials. The amended Form ID requires additional new disclosures regarding the applicant, its account administrators and certain other contacts, including disclosures regarding whether these individuals have been found to have violated securities laws and whether the applicant is in good standing in its place of incorporation. The account administrators can be (i) employees of the filer or an affiliate of the filer or (ii) any other individual authorized by a notarized power of attorney from the filer (which must be uploaded as part of the application).

    The completed Form ID application must be signed, notarized, uploaded and submitted to the SEC for approval, which can take a number of business days. If the application is approved, the account administrator(s) will receive an email and can login to the dashboard to manage the EDGAR account, authorize additional users/admins and delegate filing authority to authorized third parties.

    Additional Resources

    The SEC has published additional materials relating to EDGAR Next and enrollment on the below websites. If you would like to discuss EDGAR Next or have any questions, we encourage you to contact one of the authors of this Alert or your attorney at Schulte Roth & Zabel.

    Authored by Adriana Schwartz, Brandon S. Gold, Arelys Reyes, and Joseph Valerio.


    [1] For the full adopting release, see EDGAR Filer Access and Account Management, SEC Release No. 33-11313 (Sept. 27, 2024), which amended Rules 10 and 11 under Regulation S-T and Form ID.

    [2] View instructions on how to obtain Login.gov credentials.

    [3] Filers who are individuals or single-member companies may have a single account administrator (although the designation of multiple account administrators is encouraged).

    [4] Between Sept. 15, 2025 and Dec. 19, 2025, existing filers may continue to enroll using the dashboard, but will not be able to make filings until they complete enrollment. Any filer who has not enrolled by December 19 will be required to submit the amended Form ID to apply for EDGAR access to make submissions and obtain SEC approval of the application.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2025 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Brandon S. Gold

    Partner

    New York – 919 Third Avenue

    More insights

  • Ensuring Lawful DEI Practices: New EEOC and DOJ Guidelines for Employers

    Ensuring Lawful DEI Practices: New EEOC and DOJ Guidelines for Employers

    CLIENT ALERT / US POLICY

    Ensuring Lawful DEI Practices: New EEOC and DOJ Guidelines for Employers

    March 20, 2025

    Read time: 3 min

    Key takeaways
    Overview

    On March 18, 2025, the Equal Employment Opportunity Commission (EEOC) and the US Department of Justice (DOJ) released two technical assistance documents to help inform what each agency views as “unlawful” discrimination related to diversity, equity, and inclusion (DEI) programs in the workplace.

    In depth

    Much of the EEOC’s and DOJ’s guidance on what they view as unlawful DEI programming was addressed in the key takeaways section of our prior publication, FAQs for Employers and Federal Contractors on Navigating the DEI Landscape. However, the technical assistance documents tacitly suggest the DOJ and EEOC will focus on two important areas in carrying out US President Donald Trump’s policy initiatives regarding DEI: (1) customer or client preferences and (2) anti-bias trainings.

    Customer or Client Preferences

    In the document What You Should Know About DEI-Related Discrimination at Work, the EEOC stated, “client or customer preference is not a defense to race or color discrimination.” This calls for employers to tread carefully when responding to customer requests for data regarding the demographics of those performing work on projects relating to the customers. And, of course, employers should not make work assignment decisions based on race, color, religion, sex, or national origin except in the rare circumstance that a bona fide occupational qualification (BFOQ) relates to one of those innate characteristics.

    Anti-Bias Trainings

    The EEOC and DOJ documents suggest that DEI-related trainings, such as anti-bias trainings, can give rise to a viable hostile work environment claim. During his first term, President Trump issued an executive order banning anti-bias trainings, but that executive order was struck down as an unconstitutional infringement on First Amendment protections. It appears the EEOC and DOJ may revisit that issue but in a more tempered approach to mitigate against a constitutional challenge.

    Key Takeaways

    The EEOC’s and DOJ’s technical assistance documents do not constitute binding authority because (1) the agencies did not issue the documents as part of the required rulemaking process and (2) the Supreme Court of the United States’ decision in Loper Bright Enterprises v. Raimondo held that federal courts are not required to defer to federal agency guidelines when adjudicating civil and criminal cases. Nonetheless, the technical assistance documents provide a view into how federal agencies intend to define unlawful DEI programming, and employers should use them as a resource when working with their legal counsel to audit existing DEI programs and policies.

    Authors

    Alivia Combe-DuQuet

    Associate

    Chicago

    More insights

  • New SEC Leadership Signals Continued Focus on FDA-Related Disclosures

    New SEC Leadership Signals Continued Focus on FDA-Related Disclosures

    ARTICLE / CLIENT ALERT

    New SEC Leadership Signals Continued Focus on FDA-Related Disclosures

    March 20, 2025

    Read time: 9 min

    Key takeaways
    Overview

    Lawyers inside and outside the US Securities and Exchange Commission (SEC) have speculated that the agency’s new leadership will take a “lighter touch” when it comes to enforcement. The ultimate approach of the new SEC remains unknown until those appointments are finalized, and the transition is complete. In the meantime, recent actions indicate that the incoming SEC, like its predecessors, will continue to police misleading statements in filings and press releases regarding the US Food and Drug Administration’s (FDA) review of drug and medical device applications. Relatedly, the SEC is expected to continue to pursue insider trading actions arising from FDA developments.

    In depth

    Current SEC Enforcement Regarding FDA-Related Information

    On March 12, 2025, the SEC filed suit against three former Allarity Therapeutics, Inc. executives for allegedly scheming to conceal harsh feedback from the FDA regarding Allarity’s flagship cancer drug candidate. The SEC alleged that from February 2020 to February 2022, the executives “schemed to conceal from investors harsh critique levied by the [FDA] about the approval prospects for Allarity’s flagship cancer drug candidate, dovitinib.” Statements from the FDA in February 2020 purportedly communicated that dovitinib would not be approved for sale to the public absent a new drug trial. In an effort to raise money from investors, the executives held out Allarity’s existing drug application for dovitinib based on old trial data as viable. The SEC contended that after Allarity submitted the drug application in December 2021 without a new drug trial, Allarity listed its stock and secured millions in investments in large part based on the professed viability of dovitinib. Almost two months later, Allarity revealed problems with the drug application when it announced that the FDA refused to review the application. The next trading day, Allarity’s share price closed down approximately 31%.

    The SEC brought claims for violations of anti-fraud provisions of the federal securities laws. The SEC seeks permanent injunctions, disgorgement, civil penalties, and officer and director bars. The case is ongoing. Relatedly, the SEC simultaneously instituted administrative proceedings against Allarity based on similar allegations. Allarity consented to the entry of a cease-and-desist order and the payment of a $2.5 million penalty without admitting or denying the SEC’s findings.

    The FDA faces especially tight constraints on the valuable human and technical resources that must be invested into the drug, device, and biologics approval processes. Consequently, the FDA often rejects outright incomplete new drug application (NDA) submissions, as well as submissions that ignore basic input that it previously afforded. Drug companies and the consultants they rely on are keenly aware of these constraints, their potential impact on product review and approval timeframes, and, in turn, their potential impact on investments in the company and prospects for commercial development. Drug sponsors typically meet with the FDA prior to submitting an NDA to align planning and expectations.

    Improper disclosure or use of information gleaned from these meetings may result in an SEC investigation and charges. During the course of its Allarity investigation, for example, the SEC obtained minutes of a meeting between FDA staff and Allarity officials, which allegedly reflected the FDA staff’s admonition not to submit an application before conducting further testing. The SEC then used this information to challenge disclosures made by Allarity.

    On March 7, 2025, in another case, the SEC charged Acadia Pharmaceuticals Inc.’s former drug safety official with insider trading. The SEC alleged that the safety official exercised nearly all of his vested options and sold the underlying shares in advance of the company’s announcement of negative FDA developments. The safety official allegedly traded based on information that made him “increasingly confident” that the FDA was going to reject the company’s supplemental application to expand the use of its drug to treat Parkinson’s disease. Based on the SEC’s allegations, the official avoided losses of approximately $1.3 million. Without denying the allegations, the safety official consented to a judgment that included a permanent injunction, a five-year officer and director bar, authorization for the court to determine disgorgement, and civil penalty. The US Attorney’s Office for the Southern District of California also filed criminal charges.

    Recent Examples of SEC-FDA Partnership Enforcement Under the Prior Commission

    The Allarity case echoes enforcement actions filed toward the end of the last SEC administration. On December 3, 2024, the SEC filed settled charges against Kiromic BioPharma, Inc. and its then-two most senior officers for failing to disclose material information about the company’s two cancer fighting drug candidates before, during, and after a follow-up public offering that raised $40 million. The SEC’s findings included that the company violated Exchange Act Rule 13a-15(a) for not maintaining the requisite disclosure controls. The SEC also found that two weeks before the public offering, the FDA notified the company that it had placed the drug candidates on clinical hold – an order to delay the proposed clinical investigations. The FDA notified the company that it found its submission “grossly deficient,” and its lack of information prevented the FDA from assessing the risk of the product. The SEC challenged language in the company’s offering materials speculating that the FDA “could issue a clinical hold” and identifying the risk that clinical trials may not recommence “if the FDA imposes a clinical hold.” According to the SEC, “[d]espite disclosing the hypothetical risk of a clinical hold and the potential negative consequences on Kiromic’s business, Kiromic failed to disclose the material information that the FDA had already issued clinical holds.”

    Whistleblower complaints prompted an internal investigation, which led Kiromic to remediate and file a Form 8-K revealing the deficient disclosures. By doing so, the company avoided a penalty while consenting to an order that it cease and desist from violating provisions of the securities laws that do not require scienter. The two former executives agreed to pay penalties of $125,000 and $20,000, respectively, and a three-year officer and director bar was imposed on one of them.

    SEC enforcement cases are not confined to misrepresentations regarding the FDA’s review of an NDA. The SEC also has brought cases concerning misleading disclosures regarding the results of clinical trials following FDA clearance. On September 26, 2024, the SEC announced that Cassava Sciences, Inc., its founder and former CEO, and former senior vice president of neuroscience agreed to pay more than $40 million to settle charges related to misleading statements about the results of a Phase 2 clinical trial for the company’s purported treatment for Alzheimer’s disease. The SEC’s complaint displayed a detailed understanding of the complexities of the clinical trial process and the importance of unbiased “blinded,” “biomarker,” and “cognitive” testing. Without admitting or denying the allegations, the company and the two former executives consented to civil injunctions and agreed to pay penalties of $40 million, $175,000, and $85,000, respectively. The two former officers also consented to officer and director bars.

    SEC-FDA Partnership

    The SEC’s working knowledge of the FDA review process is likely a by-product of formal collaboration between the SEC and the FDA. In 2004, the SEC and the FDA announced a partnership to enhance their cooperation in identifying and investigating securities law violations by public companies. This partnership established a streamlined process for the FDA to refer potential violations to the SEC, designated contacts within the FDA to assist with SEC information requests, and expedited sharing of nonpublic information between the agencies. These measures aimed to strengthen securities law enforcement and protect investors from misleading statements from life sciences companies. Pursuant to this partnership, the SEC has worked with the FDA to police misleading statements in filings and press releases regarding FDA review of NDAs and medical device applications.

    The FDA’s sharing of nonpublic information also helps the SEC identify insider trading that occurs in advance of public disclosure. That collaboration builds on the SEC’s already robust ability to use technology to detect unusual trading patterns and to connect traders who share information.

    *          *          *

    All signs indicate that while the SEC may be taking a lighter enforcement touch in certain areas, it will continue to police (1) misleading statements in filings and press releases regarding FDA review of a company’s drug and medical device applications and (2) trading on the basis of positive or negative nonpublic information in advance of disclosed FDA-related information.

    Counsel should give serious thought to the possible disclosure in SEC filings whenever FDA product review processes may impact a company’s future direction and possibility of success. Life sciences counsel know that clients can be sensitive about disclosing FDA feedback that expresses concerns or doubts relating to a product’s planned approval path. Cases such as Allarity and Kiromic strongly suggest, however, that the FDA shares the bad news it delivers to companies during (or leading up to a) review with the SEC staff. FDA collaboration also apparently helps the SEC to pursue enforcement when companies, such as Cassava Biosciences, allegedly omit disclosure of challenging clinical developments that occur outside of FDA review. It may be more prudent, then, for the company to disclose the FDA’s expressed concerns (or the clinical setback) without delay and – when possible – offer a serious rationale as to why the company believes its path forward is appropriate and should prove successful. Of course, the timing and extent of such disclosure decisions often involve careful fact-based considerations of materiality and context.

    Companies in this space may avoid this scrutiny by carefully reviewing their FDA application disclosures and updating disclosure controls. Companies also should give attention to their insider trading policies and procedures, such as trading blackouts, in connection with these events.

    Rachel Peltzer and Andrew Lang-Reyes also contributed to this article.

    Authors

    Jeff Weinstein

    Counsel

    Washington, DC

    Paul M.G. Helms

    Partner

    Chicago, Washington, DC

    More insights